LAUSR

Keloids, a common and frequently occurring condition in plastic surgery and dermatology, show tumor-like characteristics such as treatment resistance and a high recurrence rate (1). Keloids are a product of abnormal healing after skin trauma and often cause symptoms such as itching, pain, and local paresthesia within the growth range (2, 3). The diagnosis of keloids generally requires a clinical physical examination after keloid formation. Keloids cannot currently be predicted at the genetic level at an early stage; thus, once keloids are formed in the postoperative incision, the surgical results, especially the surgical results of plastic surgery, will be seriously affected. Therefore, screening and identifying predictive markers of keloids has broad prospects in experimental research and clinical applications of keloids. We recently read the article by Xie et al. entitled “Single-Cell Sequencing Analysis and Weighted Co-Expression Network Analysis Based on Public Databases Identified That TNC Is a Novel Biomarker for Keloid”, published in December 2021 (4). The authors identified a novel keloid biomarker, Tenascin-c(TNC), by single-cell analysis, weighted co-expression network analysis, and differential gene analysis, and verified TNC expression by RNA-sequencing in clinical keloid samples. These bioinformatic approaches identified a promising therapeutic target and provided a novel diagnostic marker for keloids. However, the mechanism of TNC’s role in the pathological process of keloids has not been fully elucidated. The function and mechanism of TNC in keloids still